ABSTRACT
Rationale Pneumonia is a respiratory condition with complex aetiology. Host genetic variation is thought to contribute to individual differences in susceptibility and symptom manifestation.
Methods We analysed pneumonia data from the UK Biobank (14,780 cases and 439,096 controls) and FinnGen (9,980 cases and 86,519 controls). We perform genome-wide association study (GWAS) meta-analysis, gene-based test, colocalisation, genetic correlation, latent causal variable and polygenic prediction in an independent Australian sample (N=5,595) to draw insights into the genetic aetiology of pneumonia risk.
Results We identify two independent loci on chromosome 15 (lead SNPs rs2009746 and rs76474922) to be associated with pneumonia(p<5e-8). Gene-based tests revealed eighteen genes in chromosomes 15,16 and 9, including IL127, PBX3, APOBR and smoking related genes CHRNA3/5, associated with pneumonia. Evidence of HYKK and PBX3 involvement in pneumonia risk was supported by eQTL colocalisation analysis. We observed genetic correlations between pneumonia and cardiorespiratory, psychiatric and inflammatory related traits. Latent causal variable analysis suggests a strong genetic causal relationship cardiovascular health phenotypes and pneumonia risk. Polygenic risk scores (PRS) for pneumonia significantly predicted self-reported pneumonia history in an independent Australian sample, albeit with a small effect size (OR=1.11 95%CI=[1.04-1.19], p<0.05). Sensitivity analyses suggested the associations in chromosome 15 are mediated by smoking history, but the association of genes in chromosome 16 and 9, and polygenic prediction were robust to adjustment for smoking.
Conclusions Altogether, our results highlight common genetic variants, genes and potential pathways that contribute to individual differences in susceptibility to pneumonia, and advance our understanding of the genetic factors underlying heterogeneity in respiratory medical outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was conducted using data from the UK Biobank resource under application number 25331. Data collection for the Australian Genetics of Depression Study was possible, thanks to funding from the Australian National Health & Medical Research Council (NHMRC) to N.G.M. (GNT1086683). A.I.C. and K.X.V.P. are both supported by UQ Research Training Scholarships from The University of Queensland (UQ). P.F.K. is supported by an Australian Government Research Training Program Scholarship from Queensland University of Technology (QUT). M.E.R. thanks support of the NHMRC and Australian Research Council (ARC), through a NHMRC-ARC Dementia Research Development Fellowship (GNT1102821).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Finngen Biobank was evaluated and approved by the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District. The UK Biobank study was approved by the National Health Service National Research Ethics Service (ref. 11/NW/0382) and all participants provided written informed consent to participate in the UK Biobank study. Information about ethics oversight in the UK Biobank can be found at https://www.ukbiobank.ac.uk/ethics/. Regarding the AGDS, all participants provided informed consent prior to participating in the study. This study and all questionnaires used for AGDS were approved by the QIMR Berghofer Human Research Ethics Committee.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The GWAS summary statistics and results for the GWAS downstream analyses will be made available after peer-review. Code used for this study and results are available upon request.
